Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Arlen

Showing results (141-150 of 171) with videos related to

Pageof 18
Sort By:
The Journal of Urology|April 20, 2010
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancerWilliam D Figg, Sukyung Woo, Wenhui Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal CancerRichard D Kim, Nilofer S Azad, Michael A Morse, et al.
The Journal of Urology|August 20, 2008
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancerJames L Gulley, Jeanny B Aragon-Ching, Seth M Steinberg, et al.
BJU International|January 22, 2009
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancerJeanny B Aragon-Ching, Lokesh Jain, James L Gulley, et al.
Pediatric Radiology|March 19, 2020
Accuracy of subjective vesicoureteral reflux timing assessment: supporting new voiding cystourethrogram guidelinesDabin Ji, Derrick E Ridley, J Damien Grattan-Smith, et al.
The Lancet. Oncology|February 14, 2012
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A Madan, Mahsa Mohebtash, Philip M Arlen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancerWilliam L Dahut, James L Gulley, Philip M Arlen, et al.
Cancer Biology & Therapy|December 17, 2005
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumorsWilliam L Dahut, Nehal J Lakhani, James L Gulley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomasJohn L Marshall, James L Gulley, Philip M Arlen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancerPhilip M Arlen, James L Gulley, Catherine Parker, et al.
Pageof 18

Showing results (141-150 of 171) with videos related to

Sort By:
Pageof 18
The Journal of Urology|April 20, 2010
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancerWilliam D Figg, Sukyung Woo, Wenhui Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal CancerRichard D Kim, Nilofer S Azad, Michael A Morse, et al.
The Journal of Urology|August 20, 2008
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancerJames L Gulley, Jeanny B Aragon-Ching, Seth M Steinberg, et al.
BJU International|January 22, 2009
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancerJeanny B Aragon-Ching, Lokesh Jain, James L Gulley, et al.
Pediatric Radiology|March 19, 2020
Accuracy of subjective vesicoureteral reflux timing assessment: supporting new voiding cystourethrogram guidelinesDabin Ji, Derrick E Ridley, J Damien Grattan-Smith, et al.
The Lancet. Oncology|February 14, 2012
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A Madan, Mahsa Mohebtash, Philip M Arlen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancerWilliam L Dahut, James L Gulley, Philip M Arlen, et al.
Cancer Biology & Therapy|December 17, 2005
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumorsWilliam L Dahut, Nehal J Lakhani, James L Gulley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomasJohn L Marshall, James L Gulley, Philip M Arlen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancerPhilip M Arlen, James L Gulley, Catherine Parker, et al.
Pageof 18